Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.59
Bid: 3.32
Ask: 3.86
Change: 0.00 (0.00%)
Spread: 0.54 (16.265%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.59
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Distribution Agreement with Agrii UK

27 Jul 2021 07:00

RNS Number : 5252G
Plant Health Care PLC
27 July 2021
 

RNS

27 July 2021

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

Plant Health Care Announces Exclusive Distribution of Harpin ab in the UK

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce a new distribution agreement with a leading distributor in the UK for exclusive access to the biostimulant Harpin αβ in all crops in the UK.

Highlights

· Harpin αβ has been shown to have exceptional grower benefits in the UK, particularly in the amenity (turf) market and in potatoes.

· Plant Health Care has reached an exclusive agreement with Agrii, a market-leading distributor in the UK.

Harpin αβ works by triggering the plant's own self defense systems, leading to a robust physiological response, in a manner similar to vaccinations in humans. The plant responds with improved crop quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased marketable yield.

Harpin αβ has been sold on a small scale in the UK for 14 years, under the brand name ProAct®. Plant Health Care has been working with Agrii, a market-leading distributor in the UK, for several years to establish the grower benefits of Harpin β. Results have been particularly exciting in the amenity sector and in potatoes. The partner and Plant Health Care have therefore reached an agreement under which the partner will have exclusive distribution of Harpin αβ in the UK.

 

In the amenity sector, both leading golf courses and well-known football clubs are now using Harpin αβ to improve the quality of their turf.

 

ProAct was launched into the potato market in 2019, where it has shown to increase the number of tubers per plant, increase marketable yield and to improve Calcium uptake for better storage.​

Jeff Tweedy, COO of Plant Health Care noted: " "We have been working on the technical benefits of Harpin αβ in the UK for some years. We now have clarity on the best opportunities for the product. This agreement with Agrii reflects our joint confidence in the growth of ProAct® sales in the UK, especially as UK farming drives towards increased sustainability.  We expect to see greater demand for biological solutions in the UK and it is exciting that this distribution agreement will mean more growers can access the yield improvement and sustainability benefits ProAct® offers. This new agreement is also an important step towards building a stronger presence for Plant Health Care in Europe, which is the world's largest market for sustainable agriculture."

 

 

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO, Tel: +1 919 926 1600

 

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Antonio Bossi Tel: +44 (0) 20 7614 5900

 

Company website: www.planthealthcare.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFZGZNLVLGMZM
Date   Source Headline
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.